The company first studied immunogenic and antibody responses to 23 peptide epitopes in preclinical trials before selecting multiple peptides for its vaccine candidate, DPX-COVID-19. The vaccine is intended to work through multiple mechanisms to prevent infection and inhibit the virus from entering cells.
Vaccine development remains on schedule, and IMV plans to conduct a phase I clinical study this summer. The company is also performing vaccination-challenge preclinical assays in animal models with the intent to publish results later this year.
Copyright © 2020 scienceboard.net